Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 609,291 | 578,665 | 568,247 | 593,641 | 564,690 |
| Gross Profit | 609,291 | 578,665 | 568,247 | 593,641 | 564,690 |
| Operating Expenses | 182,135 | 368,866 | 34,065 | 232,127 | -170,384 |
| Operating Income | 427,156 | 209,799 | 534,182 | 361,514 | 735,074 |
| Interest Expense | 79,564 | 68,668 | 65,261 | 65,761 | 66,506 |
| Other Income | 96,619 | -50,496 | -35,488 | 38,598 | 137,790 |
| Pre-tax Income | 444,211 | 90,635 | 433,433 | 334,351 | 806,358 |
| Net Income Continuous | 444,211 | 90,635 | 433,433 | 334,351 | 806,358 |
| Minority Interests | 155,994 | 60,459 | 195,084 | 126,137 | 262,371 |
| Net Income | $288,217 | $30,176 | $238,349 | $208,214 | $543,987 |
| EPS Basic Total Ops | 0.67 | 0.07 | 0.55 | 0.46 | 1.22 |
| EPS Basic Continuous Ops | 1.03 | 0.21 | 1.00 | 0.75 | 1.80 |
| EPS Diluted Total Ops | 0.67 | 0.07 | 0.55 | 0.46 | 1.21 |
| EPS Diluted Continuous Ops | 0.79 | 0.16 | 0.75 | 0.56 | 1.36 |
| EPS Diluted Before Non-Recurring Items | 1.17 | 1.14 | 1.06 | 1.15 | 1.04 |
| EBITDA(a) | $436,277 | $219,148 | $539,463 | $366,820 | $740,422 |